US Food and Drug Administration (FDA) has taken certain regulatory actions in respect of violations or deviations of US FDA regulations applicable in that country in the cases of the following Indian Pharmaceutical companies:-
1. M/s Ranbaxy Laboratories Ltd.,
2. M/s Wockhardt Ltd.,
3. M/s Hospira Healthcare India Pvt. Ltd.,
4. M/s RPG Life Sciences Ltd.,
The Drugs Controller General (India) [DCG(I)] has taken appropriate measures to ensure that the said firms manufacture drugs in compliance with the standards and Good Manufacturing Practices prescribed for them under the Drugs and Cosmetics Rules, 1945 through the system of inspections and testing of drugs.
This information was given by the Union Minister of Health & Family Welfare Shri Ghulam Nabi Azad in written reply to a question in the LokSabha today.
Tags: Food and Drug Administration, Ghulam Nabi Azad, Good manufacturing practice, India, LokSabha, Ranbaxy Laboratories, United States, Wockhardt